Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an City, 710061, Shaanxi Province, China.
Department of Infectious Diseases, Hospital of Traditional Chinese Medicine of Yuyang District, Yulin, 719000, China.
Sci Rep. 2021 Jun 28;11(1):13389. doi: 10.1038/s41598-021-92757-0.
The predictive effect of quantitative anti-hepatitis B core on double-negative HBV DNA and RNA remains unstudied. We observed dynamic changes in this measure in chronic hepatitis B patients receiving entecavir for 10 years, evaluating its predictive value for double-negative HBV DNA and RNA. Twenty-seven chronic hepatitis B patients treated with entecavir for 10 years were enrolled in this study. Liver function, quantitative anti-hepatitis B core, hepatitis B surface and e antigens, HBV DNA and RNA were measured at baseline and each follow-up. Virological response was defined as double-negative HBV DNA and RNA; serological response was defined as hepatitis B e antigen seroconversion. After antiviral therapy, quantitative anti-hepatitis B core showed an overall downward trend. Patients with virological response had significantly higher quantitative anti-hepatitis B core levels than those without virological response at baseline. Patients with serological response also had higher quantitative anti-hepatitis B core levels than those without serological response at baseline and week 24. Baseline quantitative anti-hepatitis B core level was the only independent predictor for virological and serological responses. Baseline quantitative anti-hepatitis B core level was powerfully predictive of double-negative HBV DNA and RNA in chronic hepatitis B patients receiving long-term entecavir therapy.
定量乙型肝炎核心抗体对双阴性 HBV DNA 和 RNA 的预测作用尚未研究。我们观察了接受恩替卡韦治疗 10 年的慢性乙型肝炎患者该指标的动态变化，评估其对双阴性 HBV DNA 和 RNA 的预测价值。本研究纳入了 27 例接受恩替卡韦治疗 10 年的慢性乙型肝炎患者。在基线和每次随访时检测肝功能、定量乙型肝炎核心抗体、乙型肝炎表面抗原和 e 抗原、HBV DNA 和 RNA。病毒学应答定义为双阴性 HBV DNA 和 RNA；血清学应答定义为乙型肝炎 e 抗原血清学转换。抗病毒治疗后，定量乙型肝炎核心抗体呈总体下降趋势。有病毒学应答的患者在基线时的定量乙型肝炎核心抗体水平明显高于无病毒学应答的患者。有血清学应答的患者在基线和第 24 周时的定量乙型肝炎核心抗体水平也高于无血清学应答的患者。基线定量乙型肝炎核心抗体水平是病毒学和血清学应答的唯一独立预测因素。基线定量乙型肝炎核心抗体水平是接受长期恩替卡韦治疗的慢性乙型肝炎患者双阴性 HBV DNA 和 RNA 的有力预测指标。
